A Phase II Trial of Tideglusib in Alzheimer's Disease

2015502 citationsJournal Article

Authors

Simon Lovestone · University of Oxford

for the ARGO investigators · Fundació ACE

Merçé Boada · Inserm

Bruno Dubois · Inserm

Michael Hüll · University of Turku

Juha O. Rinne · University of Turku

Hans‐Jürgen Huppertz · Instituto de Salud Carlos III

Abstract

Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. However, given the non-linear dose response, especially in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.

Topics & Keywords

Alzheimer's disease research and treatments GDF15 and Related Biomarkers Cholinesterase and Neurodegenerative Diseases

Publication Details

Published in: Journal of Alzheimer s Disease

Volume 45, Issue 1, pp. 75-88

DOI: 10.3233/jad-141959

Field-Weighted Citation Impact: 23.42

Command Palette

A Phase II Trial of Tideglusib in Alzheimer's Disease

Authors

Abstract

Topics & Keywords

Publication Details